AU2014305792C1 - Tricyclic benzoxaborole compounds and uses thereof - Google Patents
Tricyclic benzoxaborole compounds and uses thereof Download PDFInfo
- Publication number
- AU2014305792C1 AU2014305792C1 AU2014305792A AU2014305792A AU2014305792C1 AU 2014305792 C1 AU2014305792 C1 AU 2014305792C1 AU 2014305792 A AU2014305792 A AU 2014305792A AU 2014305792 A AU2014305792 A AU 2014305792A AU 2014305792 C1 AU2014305792 C1 AU 2014305792C1
- Authority
- AU
- Australia
- Prior art keywords
- mycobacterium
- compound
- pharmaceutically acceptable
- tuberculosis
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(*)(CO1)OB2O[C@@](CN)c3c2c1ccc3* Chemical compound *C(*)(CO1)OB2O[C@@](CN)c3c2c1ccc3* 0.000 description 5
- NNGNOBBIKFFDEA-ZCFIWIBFSA-N NC[C@H](c(c1c(cc2)O)c2Br)OB1O Chemical compound NC[C@H](c(c1c(cc2)O)c2Br)OB1O NNGNOBBIKFFDEA-ZCFIWIBFSA-N 0.000 description 2
- CLGYZFTZLYKYGE-ZCFIWIBFSA-N NC[C@H](c(c1c(cc2)O)c2Cl)OB1O Chemical compound NC[C@H](c(c1c(cc2)O)c2Cl)OB1O CLGYZFTZLYKYGE-ZCFIWIBFSA-N 0.000 description 2
- FATHSKDRFVSAJJ-UHFFFAOYSA-N CC(C)(C)OC(NCC(c(c1c(cc2)O)c2Br)OB1O)=O Chemical compound CC(C)(C)OC(NCC(c(c1c(cc2)O)c2Br)OB1O)=O FATHSKDRFVSAJJ-UHFFFAOYSA-N 0.000 description 1
- VZZJZKYHYSGWMK-UHFFFAOYSA-N CC(C)(C)OC(NCC1OB2OC(C)(CO)COc(cc3)c2c1c3Br)=O Chemical compound CC(C)(C)OC(NCC1OB2OC(C)(CO)COc(cc3)c2c1c3Br)=O VZZJZKYHYSGWMK-UHFFFAOYSA-N 0.000 description 1
- UHFQBHZQYVITQE-SNVBAGLBSA-N CC(C)(C)OC(NC[C@H](c1cccc(O)c11)OB1O)=O Chemical compound CC(C)(C)OC(NC[C@H](c1cccc(O)c11)OB1O)=O UHFQBHZQYVITQE-SNVBAGLBSA-N 0.000 description 1
- OAGXCFZRRVEFIB-UHFFFAOYSA-N CC(C)(CO1)OB2OC(CN)c3c2c1ccc3 Chemical compound CC(C)(CO1)OB2OC(CN)c3c2c1ccc3 OAGXCFZRRVEFIB-UHFFFAOYSA-N 0.000 description 1
- AEZWTOOSBQYMPG-UHFFFAOYSA-N CCC(c(c1c(cc2)O)c2Br)OB1OC Chemical compound CCC(c(c1c(cc2)O)c2Br)OB1OC AEZWTOOSBQYMPG-UHFFFAOYSA-N 0.000 description 1
- VLVUMBJSODXRME-UHFFFAOYSA-N CCC(c1c23)OB2OC(C)(C)COc3ccc1Br Chemical compound CCC(c1c23)OB2OC(C)(C)COc3ccc1Br VLVUMBJSODXRME-UHFFFAOYSA-N 0.000 description 1
- UIDRVQZKXPITMF-SSDOTTSWSA-N CC[C@H](c1c2c(O)ccc1Cl)OB2O Chemical compound CC[C@H](c1c2c(O)ccc1Cl)OB2O UIDRVQZKXPITMF-SSDOTTSWSA-N 0.000 description 1
- JNIRWUYWMTVDGB-HXJPCDODSA-N C[C@@](CO)(CO1)OB2OC(/C=C/N)c3c2c1ccc3Br Chemical compound C[C@@](CO)(CO1)OB2OC(/C=C/N)c3c2c1ccc3Br JNIRWUYWMTVDGB-HXJPCDODSA-N 0.000 description 1
- HFXFHBAFGFICLN-CYBMUJFWSA-N C[C@H](c1cccc(OCCOCc2ccccc2)c11)OB1O Chemical compound C[C@H](c1cccc(OCCOCc2ccccc2)c11)OB1O HFXFHBAFGFICLN-CYBMUJFWSA-N 0.000 description 1
- RZZXJVYOGAMZGS-SKDRFNHKSA-N C[C@](CO)(COc(cc1)c23)OB2O[C@H](CN)c3c1Br Chemical compound C[C@](CO)(COc(cc1)c23)OB2O[C@H](CN)c3c1Br RZZXJVYOGAMZGS-SKDRFNHKSA-N 0.000 description 1
- NNGNOBBIKFFDEA-UHFFFAOYSA-N NCC(c(c1c(cc2)O)c2Br)OB1O Chemical compound NCC(c(c1c(cc2)O)c2Br)OB1O NNGNOBBIKFFDEA-UHFFFAOYSA-N 0.000 description 1
- DIDUSPQIIVEBOF-UHFFFAOYSA-N O=Cc1cccc(OCCOCc2ccccc2)c1 Chemical compound O=Cc1cccc(OCCOCc2ccccc2)c1 DIDUSPQIIVEBOF-UHFFFAOYSA-N 0.000 description 1
- NLDFCOFDOLBIAD-UHFFFAOYSA-N OB(c1c(cc2)O)OC(CN=O)c1c2Cl Chemical compound OB(c1c(cc2)O)OC(CN=O)c1c2Cl NLDFCOFDOLBIAD-UHFFFAOYSA-N 0.000 description 1
- IAVREABSGIHHMO-UHFFFAOYSA-N Oc1cc(C=O)ccc1 Chemical compound Oc1cc(C=O)ccc1 IAVREABSGIHHMO-UHFFFAOYSA-N 0.000 description 1
- UTEHYABQAUVXFJ-UHFFFAOYSA-N [O-][N+](CC1OB2OCCOc3c2c1ccc3)=O Chemical compound [O-][N+](CC1OB2OCCOc3c2c1ccc3)=O UTEHYABQAUVXFJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017210567A AU2017210567B2 (en) | 2013-08-09 | 2017-08-03 | Tricyclic benzoxaborole compounds and uses thereof |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361864496P | 2013-08-09 | 2013-08-09 | |
| US61/864,496 | 2013-08-09 | ||
| US201361918976P | 2013-12-20 | 2013-12-20 | |
| US61/918,976 | 2013-12-20 | ||
| PCT/US2014/050370 WO2015021396A2 (en) | 2013-08-09 | 2014-08-08 | Tricyclic benzoxaborole compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017210567A Division AU2017210567B2 (en) | 2013-08-09 | 2017-08-03 | Tricyclic benzoxaborole compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2014305792A1 AU2014305792A1 (en) | 2016-03-10 |
| AU2014305792B2 AU2014305792B2 (en) | 2017-05-04 |
| AU2014305792C1 true AU2014305792C1 (en) | 2018-07-05 |
Family
ID=52462052
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014305792A Active AU2014305792C1 (en) | 2013-08-09 | 2014-08-08 | Tricyclic benzoxaborole compounds and uses thereof |
| AU2017210567A Active AU2017210567B2 (en) | 2013-08-09 | 2017-08-03 | Tricyclic benzoxaborole compounds and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017210567A Active AU2017210567B2 (en) | 2013-08-09 | 2017-08-03 | Tricyclic benzoxaborole compounds and uses thereof |
Country Status (35)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR094961A1 (es) * | 2013-03-15 | 2015-09-09 | Lilly Co Eli | 1-hidroxi-benzooxaboroles como agentes antiparasitarios |
| KR101636431B1 (ko) | 2013-07-30 | 2016-07-05 | 동아에스티 주식회사 | 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도 |
| US20160251380A1 (en) | 2013-08-09 | 2016-09-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Tricyclic benzoxaborole compounds and uses thereof |
| EP3164404B1 (en) | 2014-07-01 | 2019-04-03 | Daiichi Sankyo Company, Limited | Tricyclic benzoxaboroles as antibacterial agents |
| MA41494B1 (fr) * | 2015-02-12 | 2020-10-28 | Glaxosmithkline Ip No 2 Ltd | Composés benzoxaborole substitués en position 4 et utilisations associées |
| CR20180560A (es) | 2016-05-12 | 2019-01-25 | Anacor Pharmaceuticals Inc | Ésteres de oxaboral y sus usos |
| CN109387594B (zh) * | 2017-08-08 | 2021-01-19 | 武汉武药科技有限公司 | 一种分离和分析贝达喹啉光学异构体的方法 |
| PL3737685T3 (pl) * | 2018-01-09 | 2023-10-02 | Halcyon Labs Private Limited | Sposób wytwarzania kryzaborolu i jego związków pośrednich |
| WO2021257466A1 (en) * | 2020-06-15 | 2021-12-23 | The Global Alliance For Tb Drug Development, Inc. | Combination antibacterial composition and method for antibacterial therapy |
| CN111606850B (zh) * | 2020-07-07 | 2023-07-25 | 安徽贝克生物制药有限公司 | 贝达喹啉及其中间体的制备方法 |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
| EP4384527A4 (en) * | 2022-06-23 | 2025-09-03 | Micurx Pharmaceuticals Inc | PRODRUGS OF BORON COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS |
| CA3239096A1 (en) * | 2022-06-23 | 2023-12-28 | Shanghai Micurx Pharmaceutical Co., Ltd. | Methods and uses of boron compounds in the treatment of nontuberculous mycobacterium infections and pharmaceutical compositions for treatment of same |
| WO2024208907A1 (en) | 2023-04-05 | 2024-10-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Synthesis of 3-(aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3h)-ol |
| CN117379430A (zh) * | 2023-10-11 | 2024-01-12 | 深圳市第三人民医院(深圳市肝病研究所) | 一种地拉韦啶的用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130165411A1 (en) * | 2011-12-22 | 2013-06-27 | Micurx Pharmaceuticals, Inc. | Tricyclic boron compounds for antimicrobial therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0947498B1 (en) | 1996-12-02 | 2004-09-15 | Chisso Corporation | Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same |
| US7446236B2 (en) | 2002-12-02 | 2008-11-04 | Solvias Ag | Catalytic hydrogenation of carbon-heteroatom double bonds |
| EP2343304B1 (en) * | 2005-02-16 | 2015-06-10 | Anacor Pharmaceuticals, Inc. | Biocidal boronophthalide compounds |
| EP1856113B1 (en) | 2005-03-08 | 2016-01-06 | Agency for Science, Technology and Research | Chiral bisoxazoline catalysts |
| CN101505603A (zh) * | 2005-12-30 | 2009-08-12 | 安纳考尔医药公司 | 含硼的小分子 |
| KR20080110984A (ko) * | 2005-12-30 | 2008-12-22 | 아나코르 파마슈티칼스 인코포레이티드 | 보론함유 소분자 |
| KR100848491B1 (ko) | 2007-01-16 | 2008-07-28 | 영진약품공업주식회사 | 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법 |
| JO3396B1 (ar) * | 2007-06-20 | 2019-10-20 | Anacor Pharmaceuticals Inc | جزيئات صغيرة تحتوي على البورون |
| WO2010080558A1 (en) | 2008-12-17 | 2010-07-15 | Anacor Pharmaceuticals, Inc. | Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol |
| ES2710105T3 (es) * | 2010-04-07 | 2019-04-23 | Glaxosmithkline Llc | Proceso para preparar benzoxaboroles |
| SI3251678T1 (sl) * | 2010-09-07 | 2022-01-31 | Anacor Pharmaceuticals, Inc. | Derivati benzoksaborola za zdravljenje bakterijskih okužb |
| KR101636431B1 (ko) | 2013-07-30 | 2016-07-05 | 동아에스티 주식회사 | 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도 |
| US20160251380A1 (en) | 2013-08-09 | 2016-09-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Tricyclic benzoxaborole compounds and uses thereof |
| MA41494B1 (fr) * | 2015-02-12 | 2020-10-28 | Glaxosmithkline Ip No 2 Ltd | Composés benzoxaborole substitués en position 4 et utilisations associées |
-
2014
- 2014-08-08 US US14/387,384 patent/US20160251380A1/en not_active Abandoned
- 2014-08-08 MY MYPI2016700458A patent/MY175823A/en unknown
- 2014-08-08 EA EA201690135A patent/EA032844B1/ru unknown
- 2014-08-08 CN CN201480049562.3A patent/CN105492388B/zh active Active
- 2014-08-08 CA CA2919888A patent/CA2919888C/en active Active
- 2014-08-08 ES ES14834292T patent/ES2905413T3/es active Active
- 2014-08-08 EP EP21214787.0A patent/EP4029870A1/en not_active Withdrawn
- 2014-08-08 SM SM20220113T patent/SMT202200113T1/it unknown
- 2014-08-08 DK DK14834292.6T patent/DK3030519T3/da active
- 2014-08-08 SI SI201431939T patent/SI3030519T1/sl unknown
- 2014-08-08 HR HRP20220384TT patent/HRP20220384T1/hr unknown
- 2014-08-08 PT PT148342926T patent/PT3030519T/pt unknown
- 2014-08-08 PE PE2016000234A patent/PE20160752A1/es unknown
- 2014-08-08 HU HUE14834292A patent/HUE057365T2/hu unknown
- 2014-08-08 AU AU2014305792A patent/AU2014305792C1/en active Active
- 2014-08-08 MX MX2016001732A patent/MX375556B/es active IP Right Grant
- 2014-08-08 WO PCT/US2014/050370 patent/WO2015021396A2/en not_active Ceased
- 2014-08-08 LT LTEPPCT/US2014/050370T patent/LT3030519T/lt unknown
- 2014-08-08 SG SG11201600787PA patent/SG11201600787PA/en unknown
- 2014-08-08 BR BR112016002651-9A patent/BR112016002651B1/pt active IP Right Grant
- 2014-08-08 SG SG10201914073PA patent/SG10201914073PA/en unknown
- 2014-08-08 UA UAA201600796A patent/UA116908C2/uk unknown
- 2014-08-08 NZ NZ716350A patent/NZ716350A/en unknown
- 2014-08-08 PL PL14834292T patent/PL3030519T3/pl unknown
- 2014-08-08 AP AP2016009046A patent/AP2016009046A0/en unknown
- 2014-08-08 JP JP2016533471A patent/JP6499175B2/ja active Active
- 2014-08-08 RS RS20220108A patent/RS62887B1/sr unknown
- 2014-08-08 KR KR1020167006314A patent/KR102093783B1/ko active Active
- 2014-08-08 CN CN201811396796.1A patent/CN110003253B/zh active Active
- 2014-08-08 EP EP14834292.6A patent/EP3030519B1/en active Active
-
2016
- 2016-01-28 IL IL243874A patent/IL243874B/en active IP Right Grant
- 2016-02-03 PH PH12016500234A patent/PH12016500234B1/en unknown
- 2016-02-04 ZA ZA2016/00792A patent/ZA201600792B/en unknown
- 2016-02-07 SA SA516370551A patent/SA516370551B1/ar unknown
- 2016-02-08 CL CL2016000313A patent/CL2016000313A1/es unknown
- 2016-02-09 CR CR20160064A patent/CR20160064A/es unknown
- 2016-02-09 DO DO2016000045A patent/DOP2016000045A/es unknown
-
2017
- 2017-08-03 AU AU2017210567A patent/AU2017210567B2/en active Active
- 2017-10-24 US US15/792,251 patent/US10308668B2/en active Active
-
2019
- 2019-03-14 JP JP2019046582A patent/JP6764970B2/ja active Active
- 2019-04-16 US US16/385,547 patent/US10526352B2/en active Active
- 2019-11-26 US US16/695,253 patent/US10858376B2/en active Active
-
2020
- 2020-11-04 US US17/089,058 patent/US20210053999A1/en not_active Abandoned
-
2022
- 2022-03-01 CY CY20221100169T patent/CY1125030T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130165411A1 (en) * | 2011-12-22 | 2013-06-27 | Micurx Pharmaceuticals, Inc. | Tricyclic boron compounds for antimicrobial therapy |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017210567B2 (en) | Tricyclic benzoxaborole compounds and uses thereof | |
| US11214582B2 (en) | 4-substituted benzoxaborole compounds and uses thereof | |
| HK1219939B (en) | Tricyclic benzoxaborole compounds and uses thereof | |
| OA17674A (en) | Tricyclic benzoxaborole compounds and uses thereof. | |
| HK1240232B (en) | 4-substituted benzoxaborole compounds and uses thereof | |
| HK1240232A1 (en) | 4-substituted benzoxaborole compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 AUG 2017 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 AUG 2017 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 FEB 2018 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 FEB 2018 |
|
| HB | Alteration of name in register |
Owner name: ANACOR PHARMACEUTICALS, LLC. Free format text: FORMER NAME(S): GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED; ANACOR PHARMACEUTICALS, INC. Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED Free format text: FORMER NAME(S): GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED; ANACOR PHARMACEUTICALS, INC. |